

Karolinska Institutet

6.2 Exposure-dependent sampling

exposure-enriched controls, counter-matching

Benefits of outcome-dependent sampling Karolinska (case-control and extensions)

Large efficiency gains for rare outcome (3+ controls per case)

For binary outcome

logistic regression gives valid estimate of population OR

Matched sets/pairs (e.g. discordant twins): Valid OR from conditional logistic regression

For time-to-event outcome:

matching on time and conditional logistic regression gives valid estimate of HR under proportional hazards



Other outcome-dependent sampling case-cohort design (Lecture 6.1)

Selects a "subcohort" at baseline (to be used as the comparison group) and (usually) all cases during follow-up.

Efficiency similar to nested case-control (similar sample size)

Analysis:

Weighted Cox regression

Weights = 1 for cases

= inverse of sampling fraction for non-cases valid estimates of population HR and absolute risk



Some simple designs, for example:

Selection of the numbers of exposed and unexposed individuals (esp. where exposure is rare) in crosssectional study or at baseline of cohort study

Matched cohort design:

Frequency matching within confounder strata (matched pairs, 1:1 exposed:unexposed)

Especially useful for studies of *<u>rare exposure</u>*



> BMC Med. 2021 Nov 16;19(1):301. doi: 10.1186/s12916-021-02177-0.

COVID-19 and risk of subsequent life-threatening secondary infections: a matched cohort study in UK Biobank

Can Hou ^{1 2}, Yihan Hu ^{1 2}, Huazhen Yang ^{1 2}, Wenwen Chen ³, Yu Zeng ^{1 2}, Zhiye Ying ^{1 2}, Yao Hu ^{1 2}, Yajing Sun ^{1 2}, Yuanyuan Qu ^{1 2}, Magnús Gottfreðsson ^{4 5}, Unnur A Valdimarsdóttir ^{6 7 8}, Huan Song ^{9 10 11}

From 445,845 UK Biobank participants, 5151 individuals with a positive test result or hospitalized with a diagnosis of COVID-19 were included in the exposed group.

For each exposed individual, up to 10 unexposed randomly selected matched individuals (n = 51,402).

Cox regression analysis



Less familiar exposure-dependent sampling

.... where exposure-dependent sampling strategies incorporated into familiar design:

Two-stage sampling on a surrogate of exposure $\sqrt{}$

Exposure-enriched case-control

Exposure density sampling

Counter-matched nested case-control



Proposed for study of gene-environment interaction (high efficiency for skewed environmental exposure and rare gene)

Idea: over- (or under-) sample subjects with high/low exposure.

Does <u>not</u>need the prevalences required by two-stage design

Straightforward analysis, logistic regression

Motivating Example



- Huque et al. *Genetic Epidemiology*, 2016, 40(7), 570-578
- Earlier case-control study in 23 villages in Bangladesh to investigate:
- dose-response of water arsenic levels with skin lesions
- interaction with genetic polymorphisms

Investigators had oversampled controls with low exposure (<50µg/l) to "overcome" skewed distribution of arsenic levels

Recall from earlier lectures:



For cohort or cross-sectional data, logistic model is a "regression model" in the sense that X's can be fixed/chosen but Y random:

We model
$$P[Y = 1] = \frac{e^{\alpha + \beta X}}{1 + e^{\alpha + \beta X}}$$

Can compute prevalance from $\boldsymbol{\alpha}$

But for case-control data, we are modelling P[Y = 1 | X] *conditional on being sampled* $= \frac{e^{\alpha * + \beta X}}{1 + e^{\alpha * + \beta X}} \quad \text{where } \alpha^* = \alpha + \log_e \frac{\pi_1}{\pi_0}$

Returning to the arsenic example



- Y= case/control status, skin lesions
- X= E (arsenic exposure: well-water and toenail levels)
 - G (genetic polymorphism in X-ray repair gene (XRCC1 Arg194Trp) GE (interaction)

Assume population model:

Logit $[Y = 1|E, G] = \alpha + \beta_E E + \beta_G G + \beta_{GE} GE$

For the sampled data, the model is

Logit $[Y = 1 | E, G, S = 1] = \alpha^* + \beta_E E + \beta_G G + \beta_{GE} GE$

where S=1 depends on case/control status and high/low exposure



Using Bayes Theorem as before..

Logit $[Y = 1|E, G, S = 1] = \alpha + \log_{e} \frac{\pi_{1H}}{\pi_{0H}} + \beta_{E} E + \beta_{G} G + \beta_{GE} GE$ if X>=50 Logit $[Y = 1|E, G, S = 1] = \alpha + \log_{e} \frac{\pi_{1L}}{\pi_{0L}} + \beta_{E} E + \beta_{G} G + \beta_{GE} GE$ if X<50 Where the π_{1} and π_{0} terms are the case and control sampling probabilities, in the high π_{1H} and π_{0H} and low (π_{1L} and π_{0L}) exposure groups.

So, using low exposure as reference, the model can be written: Logit $[Y = 1|E, G, S = 1] = \alpha^* + \beta_{HL}^* I (E >50) + \beta_E E + \beta_G G + \beta_{GE} GE$ where $\alpha^* = \alpha + \log_e \frac{\pi_{1L}}{\pi_{0L}}$ and β_{HL} is the difference $\log_e \frac{\pi_{1H}}{\pi_{0H}} - \log_e \frac{\pi_{1L}}{\pi_{0L}}$

 \rightarrow straightforward logistic regression!

Power of EECC depends on:



- Exposure distribution (asymmetry)
- Ratio of high to low exposed persons in the sample
- Case:control ratio
- gene frequency





Exposure density sampling (for a time-dependent exposure)

Quick look at Cox model



Time-dependent exposure



NCC sampling and conditional logistic regression: HR for exposed (yes/no, level, duration) vs. unexposed

Cohort approach: data gathered retrospectively

Example: association of length of hospital stay with exposures during the hospitalisation (e.g. nosocomial infection)*.



Fig. 1 Example for risk set sampling: For patient A, who gets exposed at day 3, patients C–G are suitable partners by using exposure density sampling whereas only patients D, E and G can be selected using matching for time to exposure.

* M Wolkewitz, J.Beyersmann, P Gastmeier, M.Schumacher. Meth Inf Med, 2009



Fig. 1 Example for risk set sampling: For patient A, who gets exposed at day 3, patients C–G are suitable partners by using exposure density sampling whereas only patients D, E and G can be selected using matching for time to exposure.

"Matching on time to exposure":

- For each exposed person, match unexposed persons who have been in hospital at least as long as the time-to-exposure
- selected from patients who remained unexposed throughout
- Cox regression (time zero = exposure/matched)

Common in hospital epidemiology

Exposure density sampling



Same principle as incidence density sampling

unexposed can later become exposed

Removes the "time-dependent bias" (also called "survival bias")

Standard Cox regression for time-dependent covariates (with robust variance)

Potential applications:

Discontinuation of treatment in a cohort Outcome after (waiting for) treatment in clinical cohort

Countermatching



Matching

- Purpose: to make cases and controls as similar as possible
- Match on variables not of interest (confounders)
- The effect of the matching factor cannot be estimated by standard methods

Countermatching*

- Purpose: to make cases and controls as different as possible
- Countermatch on exposure or surrogate of exposure
- Wider range of exposure improves precision

Langholz and Clayton, Env. Health Persp, 1994







Estimates obtained from weighted conditional likelihood

need risk set sizes in sampling strata in study base



"Counterintuitive matching?

Cologne, commentary in Epidemiology 1997

..... still not widespread, despite:

good efficiency

ability to get estimates from standard software (weights, offset)

Custom R commands at

https://github.com/nyilin/SamplingDesignTools

data preparation not difficult



Return to transfusions and post-partum VTE

966,070 deliveries, 472 cases of VTE within 6 weeks of delivery 1:5 NCC study had 84% of sets concordant for exposure!

	\mathbf{Cohort}	1:5 NCC CLR	1:5 CM Weighted CLR
RBC units:			
1-2	2.53(1.57, 4.07)	2.69(1.45, 4.98)	2.60(1.61, 4.20)
3-5	2.79(1.44, 5.42)	3.06(1.17, 8.03)	2.84(1.45, 5.55)
>5	4.36(1.62, 11.7)	3.65(0.87, 15.3)	4.00(1.46, 10.9)
Smoking	1.51(1.13, 2.03)	1.42(1.01, 2.01)	1.51(1.07, 2.13)
Preeclampsia	2.50(1.79, 3.48)	2.15(1.37, 3.36)	1.94(1.29, 2.93)





- Many standard epidemiology designs can be made more efficient by exploiting <u>exposure-dependent</u> sampling.
- Benefit in cost-efficiency for investment in design/analysis
- Standard methods (some using re-weighting) provide valid cohort estimates
- Greatest potential for savings where exposure information is costly (e.g. molecular/genetic studies)